# EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer

> **NCT02183870** · PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 34 (actual)

## Conditions studied

- Lung Cancer
- Adenocarcinoma
- NSCLC

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT02183870
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2018-07-24
- **Final completion:** 2020-02-29
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-06-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183870, "EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*